核酸ベース治療の世界市場

核酸ベース治療の世界市場は2030年までに126億米ドルに到達

2024年に54億米ドルと推定される核酸ベース治療の世界市場は、2024年から2030年にかけてCAGR 15.1%で成長し、2030年には126億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるRNA干渉・短鎖干渉RNAは、CAGR 16.3%を記録し、分析期間終了までに85億米ドルに達すると予測されます。アンチセンスオリゴヌクレオチド分野の成長率は、分析期間のCAGRで13.3％と推定されます。

米国市場は15億米ドルと推定される一方、中国はCAGR 20.2％で成長すると予測される

米国の核酸ベース治療市場は、2024年には15億米ドルになると推定されます。世界第2位の経済大国である中国は、2030年までに28億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは20.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ11.0％と13.6％と予測されています。欧州では、ドイツがCAGR約12.0%で成長すると予測されています。

世界の核酸ベース治療市場- 主要動向と促進要因のまとめ

核酸治療薬は疾患治療の未来をどのように再定義しているのか？

核酸ベース治療は、遺伝子発現と細胞機能の精密な操作を可能にすることで、現代医学を再形成しています。アンチセンス・オリゴヌクレオチド（ASO）、低分子干渉RNA（siRNA）、マイクロRNA（miRNA）、アプタマー、メッセンジャーRNA（mRNA）などを含むこれらの治療法は、従来のタンパク質に焦点を当てたアプローチを迂回し、遺伝子レベルでの標的介入を提供します。翻訳後のタンパク質経路を調節する従来の薬剤とは異なり、核酸治療薬は転写や翻訳の段階という早い段階で介入するため、遺伝子の機能不全を修正する際に極めて高い特異性を発揮します。

この革新的なアプローチにより、ノンコーディングRNA、遺伝子融合、希少な単遺伝性疾患など、以前は「治療不可能」であった標的を治療する道が開かれました。ヌシネルセン（脊髄性筋萎縮症治療薬）やパティシラン（遺伝性トランスサイレチンを介するアミロイドーシス治療薬）のような治療薬は、ASOやsiRNAの臨床的有用性を検証しました。一方、COVID-19ワクチンによって世界的に注目されるようになったmRNA技術は、現在、腫瘍学、自己免疫疾患、個別化ワクチンなどに再利用されつつあります。この変化は、広範な介入から、高度に個別化された遺伝子レベルの医療への移行を示すものです。

どのような技術的進歩が臨床への導入と送達を支えているのか？

核酸治療の成功は、これらの壊れやすい分子を保護し、細胞特異的な取り込みを可能にするデリバリー技術にかかっています。脂質ナノ粒子（LNP）は、特にmRNAやsiRNA治療薬において、最もスケーラブルで臨床的に検証されたキャリアとして登場しました。これらのLNPは、治療薬ペイロードを分解から保護し、エンドサイトーシスを介して細胞内への侵入を促進し、細胞質内で制御された放出を引き起こします。イオン化可能な脂質のデザイン、PEG化戦略、ターゲティングリガンドなどの改良により、LNPシステムの有効性と安全性が大幅に向上しました。

LNP以外にも、ポリマーベースのナノ粒子、デンドリマー、エクソソーム、GalNAcを用いたコンジュゲートデリバリー（肝臓ターゲティング用）などが、投与経路や標的組織の幅を広げています。例えば、GalNAcを結合させたsiRNAは、慢性肝疾患に対して毎月の投与スケジュールで皮下投与を可能にしています。さらに、エレクトロポレーション、ウイルスベクター（AAV、レンチウイルス）、新規ハイドロゲルなどが、腫瘍学や中枢神経系疾患における局所的あるいは組織選択的デリバリーのためにテストされています。バイオインフォマティクス・ツールは現在、標的外への影響を回避し、細胞内安定性を高めるための配列設計の最適化において、極めて重要な役割を果たしています。

同時に、合成化学の進歩は、オリゴヌクレオチド配列の安定性、親和性、免疫原性プロファイルを向上させています。バックボーンの修飾（ホスホロチオエートなど）、糖環の変化（2'-O-メチル、2'-フルオロ）、ロックド核酸（LNA）構造などにより、薬物動態が改善され、免疫活性化が最小限に抑えられています。これらの進歩により、投与回数の増加、循環半減期の延長、毒性プロファイルの低減が可能になり、臨床採用の拡大や規制当局の承認にとって重要な要素となっています。

市場浸透を牽引している治療領域と企業は？

希少遺伝性疾患、腫瘍学、感染症が核酸治療薬採用の最前線にあります。従来の低分子化合物では不十分なことが多い希少疾患において、ASOやsiRNAは、欠陥のある遺伝子産物を回復させたり、サイレンシングしたりすることで、顕著な効果を示しています。デュシェンヌ型筋ジストロフィー、筋萎縮性側索硬化症（ALS）、バッテン病などの疾患は、臨床研究が活発に行われている主要ターゲットのひとつです。米国と欧州における希少疾病用医薬品の指定と早期承認の道は、この分野の開発者にとってより早い市場開拓を可能にしています。

核酸治療薬は、遺伝子サイレンシング、新抗原ワクチン開発、免疫細胞初期化などに使用されています。ModernaやMerckのような製薬大手との共同開発による個別化mRNAがんワクチンは、メラノーマや肺がんの後期臨床試験へと進んでいます。同時に、RNA干渉プラットフォームは、KRASやSTAT3などの腫瘍促進因子を沈黙させるよう調整されています。固形がんにおけるドラッグデリバリーの課題は依然としてハードルであるが、腫瘍内および局所デリバリー戦略により、薬剤の分布と有効性が改善されつつあります。

Ionis Pharmaceuticals、Alnylam、Moderna、BioNTech、Sarepta Therapeuticsなどの大手企業は、オリゴヌクレオチドの化学とデリバリーに関する深い専門知識を活用し、業界をリードしています。新興のバイオテクノロジー企業も、核酸治療とAI主導のドラッグ・デザインの交差点で革新を進めています。中国や韓国などの市場参入企業は、政策支援やIPの調和を通じて自国での開発を加速させており、世界の治療パイプラインへの地域からの参入を増やしています。

世界の核酸ベース治療市場の成長を促進しているものは何か？

世界の核酸ベース治療市場の成長は、遺伝病に対する意識の高まり、ワクチンプラットフォームの急速な開発、精密医療に対する需要の高まりなど、いくつかの要因によってもたらされています。ヒトゲノミクスとトランスクリプトミクスへの理解が深まったことで、疾患ターゲットとバイオマーカーの同定が容易になり、核酸介入による治療可能な適応症のプールが拡大した。

臨床的成功例は利害関係者の懐疑心を減らし、前臨床段階から臨床段階にかけての投資を加速させました。戦略的提携、ライセンシング契約、ベンチャーキャピタルからの資金調達が、RNAに焦点を当てた新興企業やデリバリー技術プラットフォームに流れ込んでいます。COVID-19 mRNAワクチンの成功は世界の検証イベントとなり、ヘルスケアシステムと規制当局に、将来のパンデミック、がん、新興疾患に対するスケーラブルで迅速な核酸療法を優先するよう促しました。

さらに、規制当局は、特にアンメットニーズの高い生命を脅かす病態を対象とする場合、これらの治療法に対してより明確なパスウェイと迅速審査プログラムを確立しています。個別化核酸療法の高額な費用に対応するため、アウトカムベースの価格設定やバリューベースの契約に支えられた償還モデルも進化しています。製造能力の拡大、薬剤設計のデジタル化、治療法の多様化により、核酸ベース治療はニッチなバイオテクノロジー用途から21世紀医療の基盤となる柱へと移行しつつあります。

セグメント

製品（RNA干渉・短鎖干渉RNA、アンチセンス・オリゴヌクレオチド、その他製品）、用途（自己免疫疾患用途、感染症用途、遺伝子疾患用途、がん用途、その他用途）、エンドユーザー（病院・クリニックエンドユーザー、学術・研究機関エンドユーザー）

調査対象企業の例

• Alnylam Pharmaceuticals
• Anima Biotech
• Arrowhead Pharmaceuticals
• BioNTech SE
• BridgeBio Pharma
• CureVac N.V.
• Dicerna Pharmaceuticals
• Dynavax Technologies
• Gilead Sciences Inc.
• Ionis Pharmaceuticals
• Moderna Inc.
• NOXXON Pharma N.V.
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Phio Pharmaceuticals Corp.
• Precision BioSciences
• ProQR Therapeutics N.V.
• Sarepta Therapeutics
• Silence Therapeutics
• Wave Life Sciences

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Nucleic Acid Based Therapeutics Market to Reach US$12.6 Billion by 2030

The global market for Nucleic Acid Based Therapeutics estimated at US$5.4 Billion in the year 2024, is expected to reach US$12.6 Billion by 2030, growing at a CAGR of 15.1% over the analysis period 2024-2030. RNA Interference & Short Interfering RNAs, one of the segments analyzed in the report, is expected to record a 16.3% CAGR and reach US$8.5 Billion by the end of the analysis period. Growth in the Antisense Oligonucleotides segment is estimated at 13.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 20.2% CAGR

The Nucleic Acid Based Therapeutics market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 20.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.0% and 13.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.0% CAGR.

Global Nucleic Acid Based Therapeutics Market - Key Trends & Drivers Summarized

How Are Nucleic Acid Therapeutics Redefining the Future of Disease Treatment?

Nucleic acid based therapeutics are reshaping modern medicine by enabling precise manipulation of gene expression and cellular function. These therapies, which include antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), microRNAs (miRNAs), aptamers, and messenger RNAs (mRNAs), offer targeted intervention at the genetic level, bypassing conventional protein-focused approaches. Unlike traditional drugs that modulate protein pathways post-translation, nucleic acid therapeutics intervene earlier-at the transcription or translation stage-enabling profound specificity in correcting genetic dysfunctions.

This transformative approach has opened doors to treating previously “undruggable” targets such as non-coding RNAs, gene fusions, and rare monogenic diseases. Therapies like nusinersen (for spinal muscular atrophy) and patisiran (for hereditary transthyretin-mediated amyloidosis) have validated the clinical viability of ASOs and siRNAs. Meanwhile, mRNA technologies-propelled to global attention by COVID-19 vaccines-are now being repurposed for oncology, autoimmune conditions, and personalized vaccines. This shift marks a transition from broad-spectrum interventions to highly individualized, gene-level medicine.

What Technological Advances Are Supporting Clinical Translation and Delivery?

The success of nucleic acid therapies hinges on delivery technologies that protect these fragile molecules and enable cell-specific uptake. Lipid nanoparticles (LNPs) have emerged as the most scalable and clinically validated carriers, particularly for mRNA and siRNA drugs. These LNPs shield therapeutic payloads from degradation, facilitate cellular entry via endocytosis, and trigger controlled release in the cytosol. Improvements in ionizable lipid design, PEGylation strategies, and targeting ligands have significantly boosted the efficacy and safety of LNP systems.

Beyond LNPs, polymer-based nanoparticles, dendrimers, exosomes, and conjugated delivery using GalNAc (for liver targeting) are expanding the range of administration routes and target tissues. For example, GalNAc-conjugated siRNAs have enabled subcutaneous administration for chronic liver conditions with monthly dosing schedules. Additionally, electroporation, viral vectors (AAV, lentivirus), and novel hydrogels are being tested for localized or tissue-selective delivery in oncology and CNS disorders. Bioinformatics tools now play a pivotal role in optimizing sequence design to avoid off-target effects and enhance intracellular stability.

Simultaneously, synthetic chemistry advancements are enhancing the stability, affinity, and immunogenicity profiles of oligonucleotide sequences. Backbone modifications (e.g., phosphorothioate), sugar ring alterations (2’-O-methyl, 2’-fluoro), and locked nucleic acid (LNA) architectures have improved pharmacokinetics and minimized immune activation. These advancements are enabling more frequent dosing, longer circulation half-lives, and reduced toxicity profiles-critical factors in expanding clinical adoption and regulatory acceptance.

Which Therapeutic Areas and Companies Are Driving Market Penetration?

Rare genetic diseases, oncology, and infectious diseases are at the forefront of nucleic acid therapeutic adoption. In rare diseases, where traditional small molecules often fall short, ASOs and siRNAs have demonstrated remarkable efficacy by restoring or silencing faulty gene products. Disorders such as Duchenne muscular dystrophy, amyotrophic lateral sclerosis (ALS), and Batten disease are among the key targets under active clinical investigation. The orphan drug designation and accelerated approval pathways in the U.S. and Europe are enabling faster market entry for developers in this segment.

Oncology represents a fast-emerging application area, with nucleic acid therapeutics being employed in gene silencing, neoantigen vaccine development, and immune cell reprogramming. Personalized mRNA cancer vaccines, developed in collaboration between pharma giants like Moderna and Merck, are advancing into late-stage trials for melanoma and lung cancer. Simultaneously, RNA interference platforms are being tailored to silence tumor drivers such as KRAS and STAT3. Delivery challenges in solid tumors remain a hurdle, but intratumoral and local delivery strategies are improving drug distribution and efficacy.

Leading players such as Ionis Pharmaceuticals, Alnylam, Moderna, BioNTech, and Sarepta Therapeutics dominate the landscape, leveraging deep expertise in oligonucleotide chemistry and delivery. Emerging biotechs are also innovating at the intersection of nucleic acid therapy and AI-driven drug design. Markets such as China and South Korea are accelerating homegrown development through policy support and IP harmonization, increasing regional participation in the global therapeutic pipeline.

What Is Fueling Growth in the Global Nucleic Acid Based Therapeutics Market?

The growth in the global nucleic acid based therapeutics market is driven by several factors, including rising genetic disease awareness, rapid vaccine platform development, and the growing demand for precision medicine. Increased understanding of human genomics and transcriptomics has enabled better identification of disease targets and biomarkers, expanding the pool of treatable indications through nucleic acid interventions.

Clinical success stories have reduced stakeholder skepticism and accelerated investments across preclinical and clinical stages. Strategic collaborations, licensing deals, and venture capital funding are flowing into RNA-focused startups and delivery technology platforms. The success of COVID-19 mRNA vaccines served as a global validation event, prompting healthcare systems and regulators to prioritize scalable and rapid-response nucleic acid therapies for future pandemics, cancer, and emerging diseases.

Moreover, regulatory agencies have established clearer pathways and expedited review programs for these therapies, especially when targeting life-threatening conditions with high unmet needs. Reimbursement models are evolving to accommodate the high costs of personalized nucleic acid therapies, supported by outcome-based pricing and value-based contracting. With expanding manufacturing capacity, digital drug design, and increasing therapeutic diversity, nucleic acid based therapeutics are transitioning from niche biotech applications to a foundational pillar of 21st-century medicine.

SCOPE OF STUDY:

The report analyzes the Nucleic Acid Based Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides, Other Products); Application (Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application, Other Applications) End-User (Hospitals & Clinics End-User, Academic & Research Institutes End-User)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• Alnylam Pharmaceuticals
• Anima Biotech
• Arrowhead Pharmaceuticals
• BioNTech SE
• BridgeBio Pharma
• CureVac N.V.
• Dicerna Pharmaceuticals
• Dynavax Technologies
• Gilead Sciences Inc.
• Ionis Pharmaceuticals
• Moderna Inc.
• NOXXON Pharma N.V.
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Phio Pharmaceuticals Corp.
• Precision BioSciences
• ProQR Therapeutics N.V.
• Sarepta Therapeutics
• Silence Therapeutics
• Wave Life Sciences

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Nucleic Acid Based Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Surge in Genetic and Rare Disease Research Throws the Spotlight on Nucleic Acid Based Therapeutics
  • Rapid Advancement in mRNA Technology Drives Breakthroughs Beyond Vaccines
  • Expansion of CRISPR and RNAi Platforms Strengthens Business Case for Nucleic Acid-Based Interventions
  • Development of Stabilized Oligonucleotides Enhances Therapeutic Efficacy and Shelf Life
  • Partnerships Between Biotech Startups and Pharma Giants Propel Pipeline Expansion
  • Regulatory Flexibility for Orphan and Breakthrough Therapies Accelerates Clinical Advancements
  • Integration of Targeted Delivery Systems Boosts Precision and Minimizes Off-Target Effects
  • Rise in Next-Generation Sequencing Capabilities Enhances Target Identification and Customization
  • Government Funding for Rare and Genetic Disorders Drives Market Entry for Nucleic Acid Therapies
  • Growing Role of AI in RNA Structure Prediction Accelerates Discovery and Development Cycles
  • Advances in Non-Viral Delivery Mechanisms Open New Pathways for Nucleic Acid-Based Drug Platforms
  • Embrace of Modular Chemistry Accelerates Scalable Production of Oligo-Based Therapeutics
  • Positive Clinical Data for Antisense and siRNA Candidates Spurs Investor Confidence
  • Emergence of Self-Amplifying RNA and Circular RNA Expands Therapeutic Potential
  • Global Demand for Pandemic-Responsive Drug Platforms Sustains Investment in RNA Toolkits
  • Rising Patient Advocacy for Genetic Cure Options Propels Demand for Novel Therapeutic Modalities
  • Integration of Companion Diagnostics Enhances Clinical and Commercial Success
  • Market Entry of CDMO Players With RNA Expertise Fuels End-to-End Development Pipelines
  • Pursuit of Multi-Target and Multi-Pathway Therapies Expands Use Cases for Nucleic Acid Drugs
  • Growing Use in Oncology, CNS, and Infectious Disease Broadens Market Penetration
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Nucleic Acid Based Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Nucleic Acid Based Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Nucleic Acid Based Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for RNA Interference & Short Interfering RNAs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for RNA Interference & Short Interfering RNAs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for RNA Interference & Short Interfering RNAs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Antisense Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Antisense Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Antisense Oligonucleotides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Autoimmune Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Autoimmune Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Autoimmune Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Infectious Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Infectious Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Infectious Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Genetic Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Genetic Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Genetic Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 29: USA Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: USA 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: Canada 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: Canada 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• JAPAN
  • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 41: Japan Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: Japan 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Japan Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: Japan 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• CHINA
  • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 47: China Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: China Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: China 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 50: China Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: China Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: China 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• EUROPE
  • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Nucleic Acid Based Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Nucleic Acid Based Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Europe 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: Europe 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• FRANCE
  • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 62: France Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: France Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: France 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 65: France Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: France Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: France 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• GERMANY
  • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Germany Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: Germany 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 71: Germany Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Germany Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: Germany 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Italy Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Italy 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 77: Italy Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Italy Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Italy 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 80: UK Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: UK Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: UK 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 83: UK Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: UK Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: UK 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 86: Spain Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Spain Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: Spain 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 89: Spain Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Spain Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: Spain 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 92: Russia Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Russia Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: Russia 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 95: Russia Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Russia Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Russia 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Rest of Europe Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Rest of Europe 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Rest of Europe Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Rest of Europe 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 105: Asia-Pacific Historic Review for Nucleic Acid Based Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Asia-Pacific 16-Year Perspective for Nucleic Acid Based Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: Asia-Pacific 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Asia-Pacific Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: Asia-Pacific 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 113: Australia Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Australia Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: Australia 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 116: Australia Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Australia Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: Australia 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• INDIA
  • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 119: India Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: India Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: India 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 122: India Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: India Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: India 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 125: South Korea Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: South Korea Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: South Korea 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 128: South Korea Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: South Korea Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: South Korea 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Asia-Pacific Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Asia-Pacific Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 137: Latin America Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 138: Latin America Historic Review for Nucleic Acid Based Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Latin America 16-Year Perspective for Nucleic Acid Based Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 140: Latin America Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Latin America Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Latin America 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 143: Latin America Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Latin America Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Latin America 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 146: Argentina Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Argentina Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Argentina 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 149: Argentina Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Argentina Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Argentina 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 152: Brazil Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Brazil Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Brazil 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 155: Brazil Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Brazil Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Brazil 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 158: Mexico Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Mexico Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Mexico 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 161: Mexico Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Mexico Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Mexico 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Rest of Latin America Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Rest of Latin America 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Rest of Latin America Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: Rest of Latin America 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 170: Middle East Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 171: Middle East Historic Review for Nucleic Acid Based Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: Middle East 16-Year Perspective for Nucleic Acid Based Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 173: Middle East Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Middle East Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: Middle East 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 176: Middle East Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Middle East Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: Middle East 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 179: Iran Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Iran Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: Iran 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 182: Iran Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Iran Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: Iran 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 185: Israel Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Israel Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: Israel 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 188: Israel Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Israel Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Israel 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Saudi Arabia Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Saudi Arabia 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Saudi Arabia Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Saudi Arabia 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 197: UAE Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: UAE Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: UAE 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 200: UAE Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: UAE Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: UAE 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Middle East Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Rest of Middle East 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Middle East Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Rest of Middle East 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• AFRICA
  • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 209: Africa Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Africa Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Africa 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 212: Africa Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Africa Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Africa 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030

IV. COMPETITION